ClearPoint Neuro adopts Fourth Amended and Restated Bylaws with universal proxy, enhanced disclosure rules

ClearPoint Neuro, Inc.

Board adopted amended bylaws effective Dec. 14, 2022, to comply with SEC universal proxy rules and recent Delaware law changes.
Enhanced procedural mechanics and disclosure requirements for stockholder director nominations and proposals.
Advance notice deadline for stockholder proposals and nominations at annual meetings has been changed.
Updates include conforming edits and ministerial changes.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ClearPoint Neuro, Inc.: Board adopted Fourth Amended and Restated Bylaws to enhance procedural mechanics and disclosure requirements for stockholder nominations and proposals, including compliance with Rule 14a-19 and changes to advance notice deadlines (effective 2022-12-14).

Change: bylaw amendment
Effective: 2022-12-14

Exact text from the filing

Effective as of December 14, 2022, the Board of Directors of ClearPoint Neuro, Inc. (the “Company”) adopted the Fourth Amended and Restated Bylaws in connection with the new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the General Corporation Law of the State of Delaware, and a periodic review of the bylaws.

View on SEC.gov

Browse all governance changes →

ClearPoint Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001285550-22-000082

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.